Company ProfilePremium

Aplus Asset Advisor Co. Ltd

Company Profile Analysis

Ticker: 244920.KS주식회사 에이플러스에셋어드바이저

ESOMAR 23 Corporate BadgeISO Certifications Badge
Aplus Asset Advisor Co. Ltd - Company showcase

Year Founded & Workforce

2007

8,897 Employees

Aplus Asset Advisor Co. Ltd logo

Aplus Asset Advisor Co. Ltd Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Aplus Asset Advisor Co. Ltd Overview

A Plus Asset Advisor is an independent insurance general agency (GA): a corporate insurance agency that is not owned by any insurer. It distributes life and non-life policies from roughly 34–35 partner insurers through a contracted salesforce that reached 8,897 planners in mid-2026. It was the first GA to list on KOSPI (2020). It earns commissions from insurers rather than underwriting risk, which makes it a capital-light, fee-based distributor. Its economics are therefore driven by planner headcount, productivity, contract persistency and commission regulation. Around this core the founder built a "Total Life Care" group: funeral and pre-need services (A+Life), real-estate brokerage (A+Realty), healthcare services, IT, and, since 2023, KOSDAQ-listed diagnostics maker Nanoentek. Revenue grew from KRW 258bn (FY2021) to KRW 682.5bn (FY2025). Since late 2025, governance has been the main investment debate. Activist Align Partners now owns about 21% and is pressing for refocus on the core GA business, disposal of non-core assets and board independence [S1][S7][S10][S12].


What the company does

A Plus Asset Advisor is a corporate insurance agency (법인보험대리점, GA). Insurers pay it commissions to sell their products through planners registered to the company. Unlike an insurer's captive (exclusive) salesforce, a GA can sell competing products from many carriers. That lets it present side-by-side comparisons to customers, which is the core of its "insurance department store" positioning. At its 2020 IPO the company said it compared and sold products from 35 insurers. It reported approximately 1.09 million customers and about 1.88 million in-force contracts excluding auto insurance (August 2020) [S21]. Later descriptions cite 34 partner insurers across life and non-life lines [S36].

The company's own self-description in Korean disclosures, as summarised by data providers, has three parts: an independent sales platform not tied to any carrier, a nationwide planner network, and an extension into comprehensive asset-management advice [S1]. An offer document cited in coverage of the 2025 tender offer describes the company's role as comparing products' coverage, expense loadings, investment returns and prices from the customer's point of view, and placing them through its planners on consignment from partner insurers [S10].

Business model and revenue model

DimensionCharacterisation
Revenue typeAlmost entirely commission/fee revenue from insurers. Product sales (diagnostic devices via Nanoentek) and service fees (funeral, real-estate brokerage) are a minority.
Product vs. service vs. subscription vs. licensingService (distribution commissions) dominates. Product revenue arrived with Nanoentek's consolidation from FY2024. Pre-need funeral contracts at A+Life have a subscription-like instalment structure. No licensing revenue identified.
Commission structureUpfront (first-year) acquisition commissions, renewal/maintenance commissions, and insurer performance incentives ("시책"). These are subject to the "1,200% rule", which caps first-year commission at 12× the monthly premium. The cap has applied to insurer-to-GA payments since 2021, and from 1 July 2026 also to GA-to-planner payments [S23].
Cost structureCommissions paid out to planners are the dominant expense. Valueline's breakdown shows FY2025 selling, general and administrative expenses (SG&A) of KRW 653bn against revenue of KRW 682.5bn [S4].
Capital intensityLow. Investment needs are mainly IT (sales-support systems), branch fit-outs, leases and planner recruitment incentives.
Revenue recognition sensitivityBrokers note that under the 1,200% rule part of the revenue is deferred, while some selling costs are recognised when paid. This mismatch made reported operating profit volatile after 2021 [S24].

Value chain position

The company sits in the distribution link of Korea's insurance value chain:

  • Insurers (manufacturers) develop and underwrite products.

  • GAs and other channels (captive agents, bancassurance, telemarketing, online) sell them.

The industry calls the separation of product manufacturing and sales "제판분리". Large insurers have increasingly spun off their salesforces into subsidiary GAs, Hanwha Life Financial Services being the leading example. This has enlarged the GA channel but also brought insurer-affiliated competitors into it [S26].

Customer types and end-markets

Retail households: the core market, buying protection products (whole life, critical illness, health, cancer, dementia, children's insurance) and savings and pension products.

Partner insurers: effectively the company's revenue counterparties (34–35 life and non-life carriers).

Group / non-core end-markets: funeral and pre-need (A+Life); senior care (A+ Hyodam Lifecare); real-estate brokerage and investment (A+Realty); healthcare services (AAI Healthcare); diagnostics and life-science instruments, sold mostly abroad (Nanoentek); IT and digital (Fine Lab); and loan brokerage (A+ Mortgage) [S18].

Independent characterisation

Stripped of the "Total Life Care" branding, the group is a mid-sized, high-growth, regulation-sensitive insurance distributor with a conglomerate overlay. In FY2025 the parent GA generated about 88% of consolidated revenue (separate revenue KRW 601.3bn vs. consolidated KRW 682.5bn) [S2][S1].

Non-GA subsidiaries added a net KRW 3.3bn to consolidated profit in FY2025 (separate net income KRW 21.3bn; consolidated KRW 24.6bn) [S17]. However, they absorb meaningful capital: non-controlling interests of KRW 91.5bn sit on the balance sheet, largely reflecting Nanoentek's outside shareholders [S5].

The investment case therefore rests on three things: GA planner productivity, how the business absorbs commission regulation, and capital allocation and governance. The activist campaign of 2025–26 targets exactly that last point.

Strategy

Stated strategic themes

  1. Grow the core GA through salesforce scale and quality. The organisation expanded to 8,897 planners (+28.8% YoY). Management emphasises protection-type products, planner retention and contract persistency as key management indicators [S7].

  2. Dual channel model. Direct (corporate-type) branches are complemented by branch-type independent profit centres, announced in 2022, to gain scale economies. The 2022 targets were 15,000 planners within five years, and 5,000 high-productivity planners plus 10,000 branch-type planners by 2027 [S20].

  3. "Total Life Care" platform. The group's three future pillars are finance, living and health. Insurance is to be linked with funeral and senior care, real estate, healthcare services and, since 2023, bio and diagnostics [S18].

  4. Respond to regulatory change. Management says it is building "sustainable growth" ahead of the commission reform and changes in financial distribution [S7].

  5. Shareholder return and governance (2026).

    • Value-up plan announced 1 Apr 2026.

    • First execution: KRW 7bn buyback, with all shares to be cancelled.

    • A comprehensive value-up programme including governance improvements was promised for 2H26 [S8][S7].

Initiative register (last 24 months)

DateInitiativeDetail / targetSource
Jun 2025Ownership realignmentFinancial investor exits half its stake; founder's sons receive gifted shares[S22]
Oct 2025Nanoentek share exchangeDirect Nanoentek stake raised to 22.63%[S19]
1 Apr 2026Corporate value enhancement plan—[S8]
14 Jul 2026KRW 7bn buyback trust~647,548 shares; trust runs to 13 Jan 2027; all shares to be cancelled[S8]
2H 2026 (pending)Comprehensive value-up programme incl. governanceSpecific plan to be published in 2H26 and implemented in stages[S7]
OngoingPlanner organisation expansion8,897 planners at Jun 2026[S7]

Medium-term financial targets.

  • No current quantitative guidance (revenue, margin, ROE, payout) was identified.

  • The 2020 IPO targets (group revenue KRW 1 trillion and net income KRW 100bn by 2024) were not achieved. FY2024 actuals were revenue KRW 515.8bn and net income KRW 10.1bn [S21][S1].

Products & Services

Core GA (parent) — insurance distribution

OfferingDescriptionTarget customerPricing / revenue modelSource
Life protection products (multiple carriers)Whole life, including the short-pay whole life products that drove 2023 sales, plus critical illness and children's policiesRetail householdsFirst-year and renewal commissions plus insurer incentives, under the 1,200% cap[S24]
Long-term non-life (health) productsHealth, cancer, dementia and similar long-term protection from non-life carriers. Management emphasised protection products in 1H26.RetailCommissions[S7]
Savings and pension insuranceAnnuity and savings-type life policiesRetailCommissions[S1]
Auto and general insuranceSold but excluded from the 1.88M in-force contract count at IPORetailCommissions[S21]
Product comparison and adviceComparison across ~34–35 carriers. Large GAs must present at least three comparable products; from Jul 2026 they must also show the commission grade (5 tiers) and ranking of recommended products.RetailEmbedded in commissions[S21], [S23]
CFP Center / Financial Clinic CenterAdvisory units led by certified financial planners providing tailored portfolios; monthly asset-management seminars (≈30,000 attendees cumulative by 2011)Mass-affluentAdvisory feeds product sales[S30]
"Bopl" (보험플러스) appInsurance-coverage analysis app with AI functionality and automated payment, described at IPORetail / plannersSupports sales[S21]
"Wepl" appHealthcare app with 24-hour health consultation and personalised reports; launch planned for Jan 2021 per IPO coverageRetail—[S21]
Sales channelsDirect (corporate-type) branches plus branch-type (independent profit-centre) channel since 2022PlannersCommission splits[S20]

Commission rates by product, carrier mix and life vs. non-life revenue split were not publicly disclosed in the sources reviewed.

Group subsidiaries

OfferingEntityDescriptionSource
Funeral and pre-need contractsA+LifeFuneral services sold on instalment membership; also acts as group holding vehicle (lead buyer of Nanoentek)[S18], [S30]
Senior / long-term careA+ Hyodam LifecareElderly care services[S18]
Real-estate brokerage and PB servicesA+RealtyComprehensive real-estate private-banking services and group property investment. Brokered the KRW 430bn A+ Asset Tower sale.[S18], [S20]
Healthcare servicesAAI HealthcareHealth-management services using a network of ~11,000 hospitals and in-house nurse counsellors[S18]
Digital ITFine LabGroup IT and digital platform development[S18]
Loan brokerageA+ MortgageLoan intermediation[S18]
In-vitro diagnostics and life-science instrumentsNanoentekProducts built on lab-on-a-chip technology combining MEMS and microfluidics. Revenue is largely export. Product lines per the company's catalogue (not re-verified here): automated cell counters, live-cell imaging and point-of-care immunoassay platforms.[S18]

Financial Narrative

Income statement

Sources:

  • Revenue, operating income, total net income and margins: DART-based [S1].

  • EBITDA, pre-tax income, tax, FY2025 attributable net income and EPS: Valueline [S4].

  • FY2021–FY2023 attributable net income and EPS: SK Securities [S24]; FY2021 and FY2023 attributable net income derived from EPS × shares.

  • DPS: [S3].

Not available: diluted EPS (no material dilutive instruments identified), and gross profit, which is not meaningful because no cost of sales is reported for the core business.

Revenue CAGR (FY2021–FY2025): (6,825 / 2,580)^(1/4) − 1 ≈ 27.5% (computed).

Trend commentary.

2021–22 (regulatory trough): Applying the 1,200% rule to insurer-to-GA commissions in 2021 cut first-year revenue while commission and operating costs stayed. Revenue fell 9.5% and operating profit collapsed to KRW 5.7bn in FY2021 and KRW 1.4bn in FY2022 [S25][S1].

FY2022 headline profit was non-operating: Net income of KRW 65.5bn came from the KOCREF 31 REIT liquidation (KRW 76.6bn of equity-method gains in 1H22 alone) [S20].

2023–24 (IFRS 17 sales boom): Insurers competed hard for new business under IFRS 17, especially short-pay whole life and children's products. Insurers also raised performance incentives that sit outside the 1,200% cap. Revenue rose 29.6% in FY2023 and 47% in FY2024; operating profit reached KRW 31.6bn [S24][S1].

FY2024 net income (KRW 10.1bn) was depressed: by a KRW 22.7bn equity-method loss in 4Q24 visible in Valueline's trailing data [S4], around the time Nanoentek moved from associate to subsidiary.

FY2025: Revenue grew 32.3% to KRW 682.5bn. Operating profit dipped 7% to KRW 29.3bn as commission and incentive costs rose faster than revenue. Net income recovered to KRW 24.7bn, up 144.8% [S8].

1H26 inflection: Revenue grew 18.4% while operating profit rose 59.3% and net income 80.9%, so margins expanded. Trailing-twelve-month (TTM) operating profit to Jun-2026 was KRW 39.0bn on revenue of KRW 742.3bn (5.3% margin) [S7][S4].

Interim periods (FY2026 year to date)

Sources: 1H26 and 1Q26 [S7][S8]. 1H25 back-calculated from reported growth rates. 2Q26 derived as 1H26 minus 1Q26. 1Q26 was a record quarterly revenue [S8].

Balance sheet

Sources: [S5].

At 30 June 2026 [S5]:

  • Total assets KRW 544.6bn

  • Cash KRW 34.6bn plus short-term financial assets KRW 84.3bn

  • Borrowings KRW 26.3bn

  • Owners' equity KRW 183.6bn

  • Book value per share KRW 8,120

Cash flow

Sources: OCF [S6]; FCF [S1]; dividends and buybacks [S3]. TTM operating cash flow to Jun-2026 was KRW 50.8bn [S6]. The KRW 7bn buyback was authorised in Jul 2026, i.e. FY2026 [S8].

Ratios

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityActivityA+ Asset stake (FY2025 business report unless noted)Latest total assets (KRW 100M)Latest net income (KRW 100M)Source

A Plus Asset Advisor (parent)

Independent GA

——

213 (separate FY2025)

[S17]

Nanoentek Co., Ltd. (KOSDAQ 039860)

Lab-on-a-chip diagnostics and life-science instruments

25.73% direct; further shares held via A+Life and AAI Healthcare (consolidated)

98015.8

[S2], [S18]

A+Life Co., Ltd.

Funeral / pre-need services

52.23%1,1906.6

[S2]

A+Realty Co., Ltd.

Real-estate brokerage, consulting and investment

88.11%474-0.59

[S2]

Fine Lab Co., Ltd.

Digital / IT services

100%18.21.2

[S2]

AAI Healthcare Co., Ltd.

Healthcare services (network of ~11,000 hospitals cited in 2023)

———

[S2], [S18]

A+ Hyodam Lifecare

Senior / long-term care

———

[S18]

A+ Mortgage

Loan brokerage

———

[S18]

“—” = not publicly disclosed.

Revenue by Segment (KRW) and Revenue by Segment (%)

MetricFY2023FY2024FY2025

Consolidated revenue (KRW 100M)

3,5095,1586,825

Parent GA separate revenue (KRW 100M)

——6,013

Non-parent revenue, net of eliminations (KRW 100M)

——812

Parent GA share of consolidated revenue (%)

——88.1

Parent separate net income (KRW 100M)

——213

Consolidated net income (KRW 100M)

117101247

Subsidiary net contribution to net income (KRW 100M)

——33

Income Statement (KRW) and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW 100M)

2,5802,7073,5095,1586,825

Revenue growth YoY (%)

-9.54.929.647.032.3

Operating income (KRW 100M)

5714126316293

Operating margin (%)

2.20.53.66.14.3

EBITDA (KRW 100M)

————576

EBITDA margin (%)

————8.4

Pre-tax income from continuing ops (KRW 100M)

————287

Income tax (KRW 100M)

————55

Net income, total (KRW 100M)

154655117101247

Net margin (%)

6.024.23.32.03.6

Net income attributable to owners (KRW 100M)

121503102—221

EPS basic, attributable (KRW)

5352,226451—979

Dividend per share (KRW)

150200200200300

Income Statement (KRW)

Metric1H20251Q20262Q20261H2026

Revenue (KRW 100M)

3,2571,8661,9903,856

Operating income (KRW 100M)

163159101260

Net income (KRW 100M)

123——222

Balance Sheet (KRW)

Metric (KRW 100M)FY2022FY2023FY2024FY2025

Total assets

3,4533,7294,7935,153

Current assets

2,0392,0743,1213,309

Cash & cash equivalents

24377262181

Short-term financial assets

1,1338761,2501,101

Total borrowings

131230327283

Short-term borrowings incl. current portion of long-term debt

26230270267

Long-term borrowings

10505717

Net debt (negative = net cash)

-1,245-724-1,185-998

Total liabilities

1,5921,8332,3552,541

Equity attributable to owners

1,4581,5041,5051,697

Non-controlling interests

403392932915

Total equity

1,8611,8952,4382,612

Goodwill

00117112

Goodwill & intangibles

4543227214

Investment property

123371369369

Working capital (current assets − current liabilities)

1,2601,0531,6591,695

Cash Flow (KRW)

Metric (KRW 100M)FY2021FY2022FY2023FY2024FY2025

Operating cash flow

————318

Capex (implied: OCF − FCF)

————99

Free cash flow

————219

Dividends declared for the fiscal year

3445454568

Share buybacks

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE, attributable (%)

12.641.36.91.613.8

ROA (%; total net income ÷ period-end assets)

—19.03.12.14.8

Current ratio (x)

—2.622.032.132.05

Debt to equity (%; borrowings ÷ total equity)

—7.012.113.410.8

Liabilities to equity (%)

—85.596.796.697.3

Asset turnover (x; revenue ÷ period-end assets)

—0.780.941.081.32

Interest coverage (x; operating income ÷ interest expense)

————9.5

Net debt to EBITDA (x; negative = net cash)

————-1.7

Dividend payout (%; declared dividends ÷ total net income)

2894418231

Region Overview

RegionFY2025

South Korea, parent GA separate revenue (KRW 100M)

6,013

Valuation Multiples (KRW) and Valuation Multiples (x)

MetricFY2021FY2022FY2023FY2024FY2025

Year-end share price (KRW)

—4,8404,3354,4108,940

Year-end market cap (KRW 100M)

—1,0949809972,021

Year-end P/B (x)

——0.650.661.19

Dividend per share (KRW)

150200200200300

Return / level

Return / levelValueBasis / source

Last close

KRW 11,790 (15-Oct-2026)

[S5]

52-week range

KRW 5,840 – 14,780

[S1]. Investing.com shows KRW 5,600 – 14,990 [S42]; vendor discrepancy.

1-year price return

+87.7% to 7-Oct-2026

[S1]

~3-year price return

≈ +188% (KRW 4,100 on 8-Sep-2023 → KRW 11,790)

Computed from [S24][S5]

~5-year price return

≈ +14% (KRW 10,300 on 19-Nov-2021 → KRW 11,790)

Computed from [S25][S5]

Since IPO

+57% vs. KRW 7,500 offer price

Computed from [S21]

Valuation Multiples

MultipleA Plus Asset AdvisorIncar Financial Service (late Aug 2026)Notes

P/E (TTM, attributable)

8.7×6.2×

A+ TTM EPS KRW 1,356 [S4]; Incar per [S28]

P/B

1.45×2.12×

A+ BPS KRW 8,120 at Jun-2026 [S5]

EV/EBITDA (TTM)

≈3.6×

Not computed

EV ≈ market cap 2,665 + borrowings 263 + NCI 915 − cash and ST financial assets 1,189 = ≈KRW 265bn; TTM EBITDA KRW 74.2bn [S4][S5]

EV/Sales (TTM)

≈0.36×

Not computed

TTM revenue KRW 742.3bn [S4]

Dividend yield

2.5%—

KRW 300 ÷ KRW 11,790

Analyst Conclusions

Guidance and expectations

Management guidance: No quantitative guidance. Management's qualitative messages are: continued planner expansion, a focus on protection products and persistency, a 2H26 comprehensive value-up and governance programme, and cancellation of the 2026 buyback shares [S7][S8].

Consensus: None available.

Run-rate (not guidance): TTM figures to Jun-2026 are revenue KRW 742.3bn, operating profit KRW 39.0bn and attributable net income KRW 30.7bn [S4].

Bull case

  1. Operating leverage is visible. 1H26 operating profit +59% on revenue +18%. ROE has recovered from 1.6% (FY2024) to 18.0%, close to Incar's level of returns. Yet the stock trades at 1.45× book vs. Incar's 2.12× [S7][S14][S28].

  2. Capital is ready to be returned. About KRW 100bn of net cash, a first buyback-and-cancel, and a pending governance programme. A 20.88% activist holder gives a credible catalyst [S5][S8][S2].

  3. Scale is growing structurally. Planners +28.8% YoY in a channel taking share from captive agents [S7][S26].

Bear case

  1. Reform threatens the recruitment model. From Jul 2026 all planner support counts within the 1,200% cap, and from 2027 commissions are paid over 4 and later 7 years. This could slow headcount growth and lift churn just as growth is being priced in [S23].

  2. Thin margins. A 4.3% operating margin (FY2025) leaves little buffer against incentive-cost spikes [S1].

  3. Governance discount may persist. Management won every AGM vote, the founder's group is increasing its stake, and Nanoentek ties up capital at minimal returns [S15][S16][S19].

Catalysts and monitorables (next 12 months)

3Q26 results (expected mid-Nov 2026): first quarter fully under the 1,200% rule for GA planners.

2H26 value-up programme: look for a formal payout or total-return policy, board-structure changes, and treatment of Nanoentek and listed equities.

Buyback: completion of the KRW 7bn programme (trust ends 13 Jan 2027) and the cancellation resolution.

January 2027: start of the commission spread and its effect on planner recruitment and retention.

FY2026 dividend (declared ~Mar 2027): and the 2027 AGM: renewed activist proposals, and the mandatory two separately elected audit-committee members for large listed companies [S43].

Ownership: further moves by the founder's group, Align or insurance-sector holders.

Analyst verdict

A Plus Asset Advisor has become a more profitable distributor than its five-year record suggests. FY2021–FY2024 combined three distortions: a regulatory trough, a one-off real-estate windfall and a subsidiary-related write-down. Those obscured the underlying trend, which is a GA that has nearly tripled revenue since FY2021 and is now converting growth into earnings. 1H26 operating profit rose 59%, and annualised ROE reached 18%.

At about 8.7× TTM earnings, 1.45× book and roughly 3.6× EV/EBITDA, with ~KRW 100bn of net cash, the valuation already discounts a good deal of regulatory and governance risk. It still sits at a discount to the closest listed peer, Incar.

The debate is no longer whether the core business works. It is whether the 2026–2029 commission reform will cap its growth, and whether the controlling shareholder will let outside shareholders capture the cash it generates.

On the first question, the evidence is incomplete. The 1,200% planner cap started only in July 2026 and the spread begins in 2027. Investors should treat 2H26–1H27 planner counts, retention and incentive costs as the decisive data.

On the second, the record is mixed:

  • Management beat the activist at the AGM and the founder's group is buying.

  • It has also raised the dividend 50%, launched the first buyback-and-cancel, and committed to a governance programme.

Our assessment is that the shares offer asymmetric but conditional upside. A credible 2H26 value-up programme could narrow the discount to peers: a formal payout policy, a plan for Nanoentek and the listed-equity portfolio, and stronger board independence. A merely cosmetic programme, combined with a reform-driven slowdown in planner growth, would likely return the stock towards book-value multiples seen before the activist entry.

The key monitorables are the 3Q26 margin, the content of the value-up announcement and January 2027 planner retention.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / background2025 compensationSource

Kwak Geun-ho (곽근호)

Chairman and co-CEO; founder; largest shareholder

Founded the company in 2007.

KRW 1.36bn (only individually disclosed director pay). Align described his pay as mostly fixed, not performance-linked, and a large share of total registered-director pay.

[S2], [S12]

Hwang Seung-mok (황승목)

Co-CEO

Appointment date and background not publicly verified in sources reviewed

Below the KRW 500M individual disclosure threshold or not disclosed

[S7]

Park Kyung-soon (박경순)

Former CEO at IPO (2020); now listed as an unregistered executive holding 0.35%

Fronted the 2020 IPO roadshow

—

[S21], [S2]

Cho Kyu-nam (조규남)

Unregistered executive; 0.47% holding

——

[S2]

Baek Hong-ki (백홍기)

Executive vice president; bought 2,000 shares in Oct 2025 (0.15% holding)

——

[S31]

Lee Je-kyung (이제경)

Outside director (elected Mar-2026 AGM, management nominee)

——

[S15]

Two audit-committee outside directors (management nominees)

Separately elected audit-committee members (elected Mar 2026)

——

[S15]

“—” = not publicly disclosed.

Major Shareholders

HolderStake (%)Date / basisSource

Kwak Geun-ho

20.20

FY2025 year-end

[S2]

Kwak Tae-min (related party)

2.68

FY2025

[S2]

Kwak Tae-ik (related party)

2.25

FY2025

[S2]

Kim Kyung-ae (related party)

0.77

FY2025

[S2]

Cho Kyu-nam (unregistered executive)

0.47

FY2025

[S2]

Shin Da-ye (related party)

0.40

FY2025

[S2]

Park Kyung-soon (unregistered executive)

0.35

FY2025

[S2]

Other related parties (5 individuals)

0.58

FY2025

[S2]

Largest shareholder and related parties, total

27.94 → 29.80

FY2025 → 5-Aug-2026 filing

[S2]

Align Partners Asset Management (incl. funds)

20.88

2-Jul-2026 large-holding report (18.05% in Feb 2026)

[S2], [S12]

National Pension Service

0.07

End-2024

[S2]

Minority shareholders (5,853 holders)

48.1

FY2025

[S2]

Competitive Landscape

Key Competitors

CompetitorTypeScale indicatorSource

Hanwha Life Financial Services

Insurer-owned GA (Hanwha Life spin-off, 2021)

FY2025 revenue KRW 2.44 trillion; net income KRW 115.8bn; 34,608 planners incl. subsidiary GAs

[S26]

Incar Financial Service (KOSDAQ 211050)

Independent listed GA

FY2025 revenue ≈KRW 1.02 trillion; operating profit KRW 94.8bn; net income KRW 71.0bn; 16,858 planners (end-2024)

[S28], [S27]

GA Korea

Independent GA

16,449 planners (end-2024); first-time entrant to Korea's top-500 companies list in 2026

[S27], [S37]

Global Financial Sales (글로벌금융판매)

Independent GA

13,088 planners (end-2024)

[S27]

KGA Asset (케이지에이에셋)

Independent GA

Top-tier GA recruiting aggressively

[S38]

Prime Asset (프라임에셋)

Independent GA

Top-tier GA recruiting aggressively

[S38]

PeopleLife

GA (Hanwha LFS subsidiary)

Acquired by Hanwha LFS

[S39]

IFC Group

GA (Hanwha LFS subsidiary)

Acquired by Hanwha LFS

[S39]

Samsung Life Financial Services

Insurer-owned GA

——

Insurers' captive salesforces and bancassurance

Competing channels

——

Peer Comparison FY2025

MetricA Plus Asset AdvisorIncar Financial ServiceHanwha Life Financial ServicesGA Korea

Revenue (KRW 100M)

6,82510,21724,397—

Revenue growth (%)

32.322.815.6—

Operating margin (%)

4.39.3——

Net margin (%)

3.66.94.7—

Planners (latest)

8,89716,85834,60816,449

R&D intensity (%)

0.5———

P/B (x, latest)

1.452.12——

Company Snapshot

8,897

Employees

2007

Founded

SWOT Analysis

Strengths

  • Rapid, sustained top-line growth. Revenue rose from KRW 258bn (FY2021) to KRW 682.5bn (FY2025), a ~27.5% CAGR [S1].
  • Operating leverage returning. 1H26 operating profit +59.3% on revenue +18.4% [S7].
  • Net cash balance sheet. ≈KRW 99.8bn net cash at FY2025; interest coverage 9.5× [S5][S4].
  • Salesforce momentum. 8,897 planners, +28.8% YoY, against industry retention pressure [S7][S27].
  • Listed-company status. First GA on KOSPI, supporting brand and recruiting [S21].
  • Track record of profitable capital recycling in real estate. KOCREF 31 returned more than 4× its ~KRW 20bn investment [S20].

Weaknesses

  • Thin margins. FY2025 operating margin 4.3% vs. Incar's 9.3% [S1][S28].
  • Volatile earnings quality. FY2022 profit came mainly from REIT gains; FY2024 net income was KRW 10.1bn after a KRW 22.7bn equity-method loss [S20][S4].
  • Capital tied up in non-core subsidiaries. Non-controlling interests of KRW 91.5bn; Nanoentek's operating profit was about KRW 0.6bn on KRW 30.5bn of revenue [S5][S19].
  • Governance concentration. Founder combines chairman and CEO roles; his KRW 1.36bn pay was the only individually disclosed director pay [S2][S12].
  • Missed IPO-era targets. KRW 1 trillion revenue and KRW 100bn net income by 2024 vs. actuals of KRW 515.8bn and KRW 10.1bn [S21][S1].
  • Inconsistent dividends. DPS fell from KRW 350 (FY2020) to KRW 150 (FY2021); five-year dividend growth has been −3.0% per year [S3][S1].

Opportunities

  • Structural shift to GAs as insurers separate manufacturing from sales [S26][S37].
  • Consolidation of small and mid-sized GAs under tighter regulation. Align explicitly urged GA M&A [S12].
  • Value-up re-rating. Buyback-and-cancel started; 2H26 governance programme pending; P/B 1.45× vs. Incar's 2.12× [S8][S28].
  • Non-core disposals (listed equities of ≈KRW 6.7bn; possibly Nanoentek) could release capital for returns [S13].
  • Ageing-related protection and care demand that fits the group's life-care ecosystem [S7][S18].
  • Compliance as a differentiator. Large-GA commission-grade disclosure may favour well-controlled GAs with low mis-selling; the large-GA mis-selling average is 0.059% [S26][S23].

Threats

  • Commission deferral from 2027 compresses planner first-year income and may raise churn [S23].
  • 1,200% rule now covers all planner support payments, constraining recruitment incentives [S41].
  • Insurer-owned GAs with deeper pockets: Hanwha LFS has 34,608 planners and KRW 115.8bn of net income [S26].
  • Planner poaching: KRW 259bn of signing bonuses industry-wide in 2022–23 [S38].
  • Ongoing activist conflict (Align at 20.88%) could distract management or polarise the shareholder base [S2][S16].
  • Equity-market exposure: KRW 6.7bn of listed shares on the balance sheet, which Align flagged as a risk [S13].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
9-Apr-2025Executive equity reporting (Baek Hong-ki's initial report base date) [S31]Insider ownership disclosure
10-Apr-2025FY2024 dividend of KRW 200 per share paid [S3]Flat dividend despite weak FY2024 profit (182% payout)
15-May-20251Q25 quarterly report filed; ROE 2.53% [S17], [S35]Low point in capital efficiency
1-Jun-2025FSC confirms commission-reform direction (spread payments, 1,200% rule for GA planners) [S33]Structural regulatory overhang for all GAs
16-Jun-2025Financial investor block-sells about half its stake; share gifts to founder's sons [S22]Overhang reduction; succession signal
14-Aug-20251H25 half-year report [S35]Base period for the 1H26 comparison
24-Oct-2025Nanoentek share exchange; direct stake 22.63% [S19]Deeper commitment to non-core subsidiary
31-Oct-2025Executive VP buys 2,000 shares at KRW 6,144 [S31]Insider buying before the activist entry
14-Nov-20253Q25 quarterly report filed [S35]—
18-Nov-2025Align tender offer at KRW 8,000 for 19.91%; stock hits limit-up [S10], [S11]Re-rating catalyst; activist entry
7-Dec-2025Scheduled end of tender period [S10], [S12]Align becomes second-largest holder (~18%)
17-Dec-2025Regulatory Reform Committee delays decision; GA industry lobbies to postpone the 1,200% rule to Jan 2027 [S33]Regulatory uncertainty
14-Jan-2026FSC adopts final commission reform (4-year spread 2027–28, 7-year from 2029; temporary 1.5% maintenance fee during the 4-year phase) [S23], [S33]Defines the 2027+ earnings model
11-Feb-2026Align open letter: 8 demands; audit-committee nominees; PBR 1.8× vs. peer Incar 3.2× [S12]Governance campaign launched
19-Feb-2026Align demands sale of KRW 6.7bn of listed equities; shares close at KRW 14,000 (≈2.4× the pre-tender price) [S13]Valuation peak region
10-Mar-2026Management silent on Align's deadline; insiders at 28.48% [S14]Proxy-fight preparation
11-Mar-2026FY2025 dividend of KRW 300 per share declared (+50%) [S3]First dividend increase since FY2022
23-Mar-2026FY2025 business report filed [S2]Primary annual disclosure
31-Mar-2026AGM: management wins all contested votes; audit-committee separate-election seats raised to two [S15]Activist defeated at the ballot
1-Apr-2026Value-up plan announced [S8]Response to market and activist pressure
Apr-2026Related parties raise stake to 29.13% using share-backed loans; Align consolidates its fund holdings [S16]Control contest continues
9-Apr-2026FY2025 dividend paid [S3]—
29-Apr-2026Align opens stakeholder "tip centre" and questions insurer buying [S16]Escalation
15-May-20261Q26 report: record quarterly revenue KRW 186.6bn; operating profit KRW 15.9bn; ROE 17.5% [S8], [S17]Earnings inflection
1-Jul-20261,200% rule applies to GA planner pay; large GAs must disclose commission grades [S23]Regulatory regime change
2-Jul-2026Align large-holding report: 20.88% [S2], [S34]Stake increased post-AGM
14-Jul-2026KRW 7bn buyback for cancellation [S8], [S9]First value-up execution
29-Jul to 5-Aug-2026Largest-shareholder filings: group stake 29.77% → 29.80% [S2]Continued creeping purchases
14-Aug-20261H26: revenue +18.4%, operating profit +59.3%, net income +80.9%; planners 8,897; ROE 18.0% [S7]Strongest half-year operating profit in the dataset
15-Oct-2026Share price KRW 11,790 (−4.0% on day); ~20% below the 52-week high [S5]Momentum cooling

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Segment (KRW): Consolidated revenue rose from KRW 3,509 in FY2023 to KRW 6,825 in FY2025.
Aplus Asset Advisor Co. Ltd — Revenue by Segment (KRW)
Series (KRW)FY2023FY2024FY2025
Consolidated revenue3,5095,1586,825
Parent GA separate revenue——6,013
Non-parent revenue, net of eliminations——812
Parent separate net income——213
Consolidated net income117101247
Subsidiary net contribution to net income——33

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. S1ETF Shopping, 에이플러스에셋 stock page (DART business-report-based financials FY2020–FY2025; price, valuation, FCF; updated Oct 2026) (etfshopping.com)
  2. S2ETF Shopping, 에이플러스에셋 company page (FY2025 business report: legal name, CEOs, founding date, address, employees, shareholders, subsidiaries, executive pay; links to DART filings) (etfshopping.com)
  3. S3ETF Shopping, 에이플러스에셋 dividend page (DPS history, payout, buyback, DART links) (etfshopping.com)
  4. S4Valueline (DataHero), income statement, consolidated K-IFRS, trailing-12-month series to 2Q26 (valueline.co.kr)
  5. S5Valueline (DataHero), balance sheet, consolidated K-IFRS FY2022–1H26; price 15-Oct-2026 (valueline.co.kr)
  6. S6Valueline (DataHero), cash flow statement, trailing series (valueline.co.kr)
  7. S7Youth Daily (청년일보), 1H26 results article, 14-Aug-2026 (youthdaily.co.kr)
  8. S8SBS Biz, KRW 7bn buyback article, 14-Jul-2026 (biz.sbs.co.kr)
  9. S9Financial News, buyback and value-up article, 14-Jul-2026 (fnnews.com)
  10. S10Dealsite, Align tender offer, 18-Nov-2025 (dealsite.co.kr)
  11. S11Asia Economy, limit-up on tender offer, 18-Nov-2025 (core.asiae.co.kr)
  12. S12Asia Economy, Align open letter and proposals, 11-Feb-2026 (view.asiae.co.kr)
  13. S13Twig / Seoul Shinmun, activist pressure on GA and listed-equity disposal demand, 19-Feb-2026 (twig24.com)
  14. S14IB Tomato, pre-AGM standoff and ROE history, 10-Mar-2026 (newstomato.com)
  15. S15Dealsite, AGM outcome, 31-Mar-2026 (dealsite.co.kr)
  16. S16Asia Economy, founder group stake build and Align response, 6-May-2026 (core.asiae.co.kr)
  17. S17Dealsite, subsidiary contribution analysis (FY2025, 1Q26) (dealsite.co.kr)
  18. S18Dealsite and Smart Today, Nanoentek acquisition, 13-Jul-2023 · smarttoday.co.kr · Dealsite group executive reshuffle, 2-Jan-2023
  19. S19Digital Today, Nanoentek stake change, 24-Oct-2025 (digitaltoday.co.kr)
  20. S20Financial News, 7-Jun-2022 · Dealsite, 8-Jun-2022 · Dealsite, 17-Aug-2022
  21. S21Korea Economic Daily, IPO article, 17-Nov-2020 (hankyung.com)
  22. S22IB Tomato, FI exit and succession, 26-Jun-2025 (newstomato.com)
  23. S23Kim & Chang newsletter, commission reform, 19-Jan-2026 · Metro Seoul, 30-Jun-2026
  24. S24SK Securities company reports on 244920 (Sep-2023, Dec-2023, Jun-2024, Dec-2024), via AlphaSquare — and related files (file.alphasquare.co.kr)
  25. S25IBK Securities (6-May-2021) and Yuanta Securities (22-Nov-2021) reports, via AlphaSquare · file.alphasquare.co.kr
  26. S26Asia Economy, Hanwha Life Financial Services FY2025, 26-Mar-2026 · Herald Economy, 17-May-2026
  27. S27CEO Score Daily, top-4 GA planner counts and retention, 12-Mar-2025 (ceoscoredaily.com)
  28. S28ETF Shopping, Incar Financial Service · Valueline, Incar
  29. S29Morningstar company profile (older address, employee count) (dfd.dr.morningstar.com.au)
  30. S30Korea Economic Daily, founder award, Dec-2011 (hankyung.com)
  31. S31Digital Today, executive share purchase, 31-Oct-2025 (digitaltoday.co.kr)
  32. S32Bizhankook, Align 2026 AGM-season review (bizhankook.com)
  33. S33Bizwatch, 17-Dec-2025 and 14-Jan-2026 commission reform coverage · news.bizwatch.co.kr
  34. S34StockHub, Align Partners 5% filings (stockhub.kr)
  35. S35IRGO filing index for 244920 · iNews24, IPO briefing, Nov-2020
  36. S36MyDailyByte company overview (34 partner insurers) (mydailybyte.com)
  37. S37CEO Score Daily, 2026 top-500 companies (GA entrants) (ceoscoredaily.com)
  38. S38Asia Economy, GA recruitment competition and FSS signing-bonus survey, 23-Sep-2024 (view.asiae.co.kr)
  39. S39Jasoseol company insight on Hanwha Life Financial Services (PeopleLife, IFC acquisitions) (jasoseol.com)
  40. S40Hanwha Investment & Securities, Incar report (GA commission pool data), 11-Jan-2022 (file.alphasquare.co.kr)
  41. S41Korea Insurance News via Dazabi, commission reform summary and persistency data (dazabi.com)
  42. S42Investing.com Korea, 244920 quote page (kr.investing.com)
  43. S43The Fact, activist AGM season review (audit-committee separate-election rule change) (news.tf.co.kr)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.